SCHEMBL27240229

SCHEMBL27240229

Cc1nc(=O)c2cc(Br)ccc2n1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
MAPK8 P45983 1/20 0.46
CASP3 P42574 3/20 0.44
CYP1A2 P05177 1/20 0.42
MCL1 Q07820 1/20 0.41
HTT P42858 2/20 0.40
MAPT P10636 2/20 0.40
RAB9A P51151 2/20 0.40
LMNA P02545 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
NPC1 O15118 1/20 0.40
TP53 P04637 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GSK3B P49841 3/20 0.39
CCNB2 O95067 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27240420 0.81 CYP1A2 (0.41) ALDH1A1MEN1KMT2AMAPK8CASP3
SCHEMBL29209057 0.78 CASP3 (0.47) ALDH1A1MEN1KMT2AMAPK8CASP3
SCHEMBL30336384 0.78 CASP3 (0.47) ALDH1A1MEN1KMT2AMAPK8CASP3
SCHEMBL958660 0.77 RAB9A (0.58) ALDH1A1MEN1KMT2ACYP1A2HTT
SCHEMBL14479468 0.76 MAPK8 (0.48) ALDH1A1MEN1KMT2AMAPK8CASP3
SCHEMBL1921514 0.75 MAPT (0.46) ALDH1A1MEN1KMT2ACYP1A2MCL1
SCHEMBL9919073 0.75 CASP3 (0.54) MEN1KMT2ACASP3HTTMAPT
SCHEMBL16292510 0.74 NQO2 (0.61) ALDH1A1MAPK8CYP1A2MCL1MAPT
SCHEMBL23589158 0.73 MAT2A (0.42) ALDH1A1MEN1KMT2AMAPK8CASP3
SCHEMBL27240419 0.73 HSD17B10 (0.50) ALDH1A1MEN1KMT2ACASP3HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4615454-A1 SOS1 INHIBITORS Acerand Therapeutics (Hong Kong) Limited (HK) 2025-09-17 EP disclosed
US-20240190868-A1 SOS1 INHIBITORS ACERAND THERAPEUTICS (HONG KONG) LIMITED (HK) 2024-06-13 US disclosed
WO-2024102952-A1 SOS1 INHIBITORS ACERAND THERAPEUTICS (USA) LIMITED (US) 2024-05-16 WO disclosed
WO-2024102952-A1 SOS1 INHIBITORS ACERAND THERAPEUTICS (USA) LIMITED (US) 2024-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190868-A1 SOS1 INHIBITORS SOS1, SOS2, SOST ALDH1A1 3287/4885MEN1 63/4885KMT2A 4304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.